142 related articles for article (PubMed ID: 37482293)
21. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.
Daïen CI; Monnier A; Claudepierre P; Constantin A; Eschard JP; Houvenagel E; Samimi M; Pavy S; Pertuiset E; Toussirot E; Combe B; Morel J;
Rheumatology (Oxford); 2009 Aug; 48(8):883-6. PubMed ID: 19423648
[TBL] [Abstract][Full Text] [Related]
22. Sarcoid-like reaction in cases treated by checkpoint inhibitors.
Paydas S
Med Oncol; 2021 Feb; 38(3):29. PubMed ID: 33598792
[TBL] [Abstract][Full Text] [Related]
23. Sarcoidosis vs. Sarcoid-like reactions: The Two Sides of the same Coin?
Tchernev G; Tana C; Schiavone C; Cardoso JC; Ananiev J; Wollina U
Wien Med Wochenschr; 2014 Jul; 164(13-14):247-59. PubMed ID: 24664574
[TBL] [Abstract][Full Text] [Related]
24. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
25. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
26. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
[TBL] [Abstract][Full Text] [Related]
27. Renal Sarcoidosis-like Reaction Induced by PD-1 Inhibitor Treatment in Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Park SD; Kim MS; Han MH; Kim YJ; Jung HY; Choi JY; Cho JH; Park SH; Kim CD; Kim YL; Lim JH
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241223
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Inhibitor-Associated Sarcoidosis Reaction in the Kidney: Case Report.
Charkviani M; Herrmann SM
Kidney Med; 2023 May; 5(5):100626. PubMed ID: 37122393
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
30. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
Nikolaou V; Sibaud V; Fattore D; Sollena P; Ortiz-Brugués A; Giacchero D; Romano MC; Riganti J; Lallas K; Peris K; Voudouri D; Lallas A; Fabbrocini G; Lazaridou E; Carrera C; Annunziata MC; Rossi E; Patri A; Rigopoulos D; Stratigos AJ; Apalla Z
J Am Acad Dermatol; 2021 May; 84(5):1310-1320. PubMed ID: 33279646
[TBL] [Abstract][Full Text] [Related]
32. [Sarcoid Granulomas Over Scars: Beyond Sarcoidosis].
Morgado F; Batista M; Cardoso JC; Gonçalo M
Acta Med Port; 2022 Mar; 35(3):218-221. PubMed ID: 34871541
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report.
Li H; Mu F; Zou B; Wang L
Medicine (Baltimore); 2023 Aug; 102(31):e34432. PubMed ID: 37543824
[TBL] [Abstract][Full Text] [Related]
34. Incidence and clinical characteristics of thyroid abnormalities in cancer patients treated with immune checkpoint inhibitors.
Cuenca D; Rodríguez-Meléndez E; Aguilar-Soto M; Sánchez-Rodríguez A; Íñiguez-Ariza N; Olivares-Beltrán G; Gerson-Cwilich R; Mercado M
Gac Med Mex; 2021; 157(3):293-297. PubMed ID: 34667315
[TBL] [Abstract][Full Text] [Related]
35. Immune-mediated hepatitis: Basic concepts and treatment.
Velarde-Ruiz Velasco JA; Tapia Calderón DK; Cerpa-Cruz S; Velarde-Chávez JA; Uribe Martínez JF; García Jiménez ES; Aldana Ledesma JM; Díaz-González Á; Crespo J
Rev Gastroenterol Mex (Engl Ed); 2024; 89(1):106-120. PubMed ID: 38485561
[TBL] [Abstract][Full Text] [Related]
36. Safety and discontinuation rate of immune checkpoint inhibitors used in patients with solid and hematological malignancies. A population based retrospective analysis.
Shahbar A; Alshamrani M; Aseeri M; Alfayea T; Alnatsheh A
J Oncol Pharm Pract; 2022 Jun; 28(4):771-776. PubMed ID: 34034557
[TBL] [Abstract][Full Text] [Related]
37. Sarcoid-like pattern in a patient with tuberculosis.
Chokoeva AA; Tchernev G; Tana C; Ananiev J; Wollina U
J Biol Regul Homeost Agents; 2014; 28(4):783-8. PubMed ID: 25620187
[TBL] [Abstract][Full Text] [Related]
38. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
39. Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report.
Torres-Zurita A; Vázquez-Montero L; Gallego-López L; Mediano-Rambla MD; de la Cruz-Merino L
Front Immunol; 2023; 14():1150128. PubMed ID: 37781378
[TBL] [Abstract][Full Text] [Related]
40. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
